McKesson and healthcare technology company Aetion have announced a collaboration to advance cancer research. The partnership is meant to advance the use of real-world evidence to aid the cancer infrastructure and help fight multiple tumor types.
The Aetion Evidence Platform will work with McKesson’s iKnowMed oncology electronic health record to improve research for an FDA project at Brigham and Women’s Hospital. The solution will improve insight, safety, and allow companies to assess the economic impact of treatments. Aetion analyzes health data from the real world to provide answers about treatments, costs, and outcomes for providers, payers, and regulatory agencies.
“This collaboration is an important step in informing rigorous standards for regulatory-grade data and analysis. Our goal is to get therapies to market faster to help life sciences companies and drive better health for patients,” said Derek Rago, vice president and general manager of Oncology Data, Evidence, and Insights at McKesson Life Sciences via release. “Based on the ability of observational studies to gain insight into treatment patterns and outcomes in clinical practice, the FDA is supportive of the expanded use of RWE to inform a variety of regulatory decisions.”
“Combining our real-world evidence platform with McKesson’s cancer data accelerates time to insight when conducting oncology analyses,” said Carolyn Magill, CEO of Aetion via release. “This collaboration enables us to provide researchers with the tools to advance cancer research with greater efficiency and precision.”
